Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-1,39
KB1182-1,09
PKN108,62108,640,63
Msft-0,13
Nokia5,936,020,64
IBM1,10
Mercedes-Benz Group AG57,6757,690,05
PFE0,40
16.02.2026 18:00:58
Indexy online
AD Index online
select
AD Index online
 

  • 14.02.2026 2:00:00
Universe Pharma Rg (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (USD)
2,86 -1,72 -0,05 46 254
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 16.02.2026
Popis společnosti
Obecné informace
Název společnostiUniverse Pharmaceuticals Inc
TickerUPC
Kmenové akcie:Ordinary Shares
RICUPC.O
ISIN-
Poslední známé roční výsledky30.09.2025
Poslední známé čtvrtletní výsledky30.09.2025
Počet zaměstnanců k 30.09.2025 216
Akcie v oběhu k 30.09.2025 563 338
MěnaUSD
Kontaktní informace
Ulice265 Jingjiu Avenue
MěstoJI'AN
PSČ343100
ZeměChina
Kontatní osobaTina Xiao
Funkce kontaktní osobyIR Contact Officer
Telefon867 968 403 309
Kontatní telefon19 176 090 333

Business Summary: Universe Pharmaceuticals Inc is a China-based holding company mainly engaged in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives (TCMD) products targeting the elderly. Through its subsidiary, the Company sells TCMD products, biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces (TCMPs), and dietary supplements manufactured by third-party pharmaceutical companies. Its TCMD products fall into two categories: chronic condition treatments as well as cold and flu medications, including Guben Yanling Pill, Shenrong Weisheng Pill, Fengshitong Medicinal Liquor, Isatis Root Granule and Qiangli Pipa Syrup. Its major customers are pharmaceutical companies, hospitals, clinics and drugstore chains. The Company mainly conducts its businesses within the Chinese market.
Financial Summary: BRIEF: For the fiscal year ended 30 September 2025, Universe Pharmaceuticals Inc revenues decreased 22% to $17.9M. Net loss decreased 58% to $3.7M. Revenues reflect Sales of third-party products segment decrease of 49% to $4.6M, Sales of TCMD products segment decrease of 5% to $13.3M. Lower net loss reflects China (Mainland) segment loss decrease of 64% to $2.9M.
Odvětvová klasifikace
TRBC2012Alternative Medicine
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSMedicinal and Botanical Manufacturing
NAICSPharmaceutical Preparation Manufacturing
NAICSDrugs and Druggists' Sundries Merchant Wholesalers
NAICSMedical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers
NAICSOther Grocery and Related Products Merchant Wholesalers
NAICSOffices of Other Holding Companies
NAICS2007Medicinal & Botanical Mfg
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Drugs and Druggists' Sundries Merchant Wholesalers
NAICS2007Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers
NAICS2007Other Grocery and Related Products Merchant Wholesalers
NAICS2007Offices of Other Holding Companies
NAICS1997Medicinal and Botanical Manufacturing
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Drug, Drug Proprietaries and Druggists' Sundries Wholesalers
NAICS1997Medical, Dental and Hospital Equipment and Supplies Wholesalers
NAICS1997Other Grocery and Related Products Wholesalers
NAICS1997Offices of Other Holding Companies
SICMedicinals And Botanicals
SICPharmaceutical Preparations
SICDrugs/proprietaries/sundries
SICMedical And Hospital Equipment
SICGroceries/related Products, Nec
SICHolding Companies, Nec



  • Poslední aktualizace: 16.02.2026
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, Chief Executive OfficerGang Lai54
Chief Financial Officer, DirectorLin Yang46
Chief Operating OfficerBaochang Liu42